Telomolecular Corp. has commenced studies and plans to develop, test, and ready a rejuvenating skin cream for
initial market and resale in the domestic United States and abroad possibly within 48 months. Tests have commenced in fibroblast
cells, which make up a layer of the skin, and there is evidence that the product may make a big impact on aged skin,
resulting in a reduction of wrinkles and discoloration, and leading to improvements in elasticity, texture, and sheen.
|
Pharmaceutical applications that treat specific diseases or rejuvenate the body are primary long-term goals of the company.
We believe such applications will transform human health.
The development of IV administered pharmaceuticals presents fewer hurdles than the production of oral applications. Both
applications are based on the creation of a nanoparticle delivery mechanism and a TERT analogue, variant, or synthetic
DNA nanocircles; however, IV administration of pharmaceuticals tends to have superior uptake and distribution potential.
Oral applications, once developed, tend to be less expensive to administer and more popular to buy.
|
